Latest Breaking News On - Signs diary - Page 1 : comparemela.com

New Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

Robert bissonnetteInnovaderm research incInternational psoriasis council robert bissonnetteJanssen researchInternational psoriasis councilPsoriasis areaSeverity indexNew england journalInnovaderm researchDermatology life quality indexPsoriasis symptomsSigns diaryReceptor antagonist peptideInvest dermatolIl 23Jnj 77242113

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively.NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Compan.

United statesScott plevyDineshv patelCorey davisProtagonist therapeutics incNetwork of companiesExchange commissionTakeda pharmaceuticals co ltdProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diary

Guselkumab Shows Significant Scalp Psoriasis Clearance in People of Color

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported HRQOL outcomes in patients of color.

New yorkUnited statesAndrew alexisDerm hawaiiScalp specific investigator global assessmentPsoriasis scalp severity indexScalp surface areaScalp itch numeric rating scalePsoriasis symptomsSigns diaryDermatology life quality indexHealth related qualityClinical dermatologyVice chairWeill cornell medicineLead study

New England Journal of Medicine Publishes Efficacy and Safety Data

New England Journal of Medicine Publishes Efficacy and Safety Data .

United statesScott plevyDineshv patelNews networkProtagonist therapeutics incProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diaryDermatology life quality indexExecutive vice presidentTherapeutic head

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDineshv patelCorey davisScott plevyProtagonist therapeutics incTakeda pharmaceuticals co ltdNetwork of companiesExchange commissionProtagonist therapeuticsNew england journalPsoriasis areaSeverity indexGlobal assessmentPatient reported outcomesPsoriasis symptomsSigns diary